Kessendri Reddy1, Adrie Bekker2, Andrew C Whitelaw1, Tonya M Esterhuizen3, Angela Dramowski4. 1. Division of Medical Microbiology and Immunology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 2. Division of Neonatology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 3. Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 4. Division of Paediatric Infectious Diseases, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Abstract
BACKGROUND: Analysis of hospital-acquired bloodstream infection (HA-BSI) trends is important to monitor emerging antimicrobial resistance (AMR) threats and guide empiric antibiotic choices. METHODS: A retrospective 10-year review of neonatal HA-BSI was performed at Tygerberg Hospital's neonatal unit in Cape Town, South Africa. Neonatal clinical and laboratory data from 2014 to 2018 (Period 2) was compared with published data from 2009 to 2013 (Period 1). RESULTS: The neonatal unit's HA-BSI rate declined between periods from 3.9/1000 inpatient-days in Period 1 to 3.3/1000 inpatient-days in Period 2 (p = 0.002). Pathogen yield and blood culture contamination rate were unchanged (11.0% to 10.4%, p = 0.233; 5.1% to 5.3%, p = 0.636 respectively). Gram-negative pathogens predominated (1047/1636; 64.0%); Klebsiella species, Staphylococcus aureus, Serratia marcescens, Enterococcus species and Acinetobacter baumannii were the most frequent pathogens. Extended spectrum beta-lactamase production was observed in 319/432 (73.8%) of Klebsiella species, methicillin resistance in 171/246 (69.5%) of Staphylococcus aureus and extensive drug resistance in 115/137 (83.9%) of Acinetobacter species (2009-2018). The crude mortality rate of neonatal HA-BSI episodes increased from Period 1 to Period 2 from 139/717 (19.4%) to 179/718 (24.9%) (p = 0.014), but HA-BSI attributable mortality remained unchanged (97/139 [69.8%] vs 118/179 [65.9%], p = 0.542). The in-vitro activity of piperacillin-tazobactam and amikacin declined during Period 2 (74.6% to 61.4%; p<0.001). CONCLUSION: Although HA-BSI rates declined in the neonatal unit, antimicrobial resistance rates in BSI pathogens remained high. Continuous BSI surveillance is a valuable tool to detect changes in pathogen and AMR profiles and inform empiric antibiotic recommendations for neonatal units in resource-limited settings.
BACKGROUND: Analysis of hospital-acquired bloodstream infection (HA-BSI) trends is important to monitor emerging antimicrobial resistance (AMR) threats and guide empiric antibiotic choices. METHODS: A retrospective 10-year review of neonatal HA-BSI was performed at Tygerberg Hospital's neonatal unit in Cape Town, South Africa. Neonatal clinical and laboratory data from 2014 to 2018 (Period 2) was compared with published data from 2009 to 2013 (Period 1). RESULTS: The neonatal unit's HA-BSI rate declined between periods from 3.9/1000 inpatient-days in Period 1 to 3.3/1000 inpatient-days in Period 2 (p = 0.002). Pathogen yield and blood culture contamination rate were unchanged (11.0% to 10.4%, p = 0.233; 5.1% to 5.3%, p = 0.636 respectively). Gram-negative pathogens predominated (1047/1636; 64.0%); Klebsiella species, Staphylococcus aureus, Serratia marcescens, Enterococcus species and Acinetobacter baumannii were the most frequent pathogens. Extended spectrum beta-lactamase production was observed in 319/432 (73.8%) of Klebsiella species, methicillin resistance in 171/246 (69.5%) of Staphylococcus aureus and extensive drug resistance in 115/137 (83.9%) of Acinetobacter species (2009-2018). The crude mortality rate of neonatal HA-BSI episodes increased from Period 1 to Period 2 from 139/717 (19.4%) to 179/718 (24.9%) (p = 0.014), but HA-BSI attributable mortality remained unchanged (97/139 [69.8%] vs 118/179 [65.9%], p = 0.542). The in-vitro activity of piperacillin-tazobactam and amikacin declined during Period 2 (74.6% to 61.4%; p<0.001). CONCLUSION: Although HA-BSI rates declined in the neonatal unit, antimicrobial resistance rates in BSI pathogens remained high. Continuous BSI surveillance is a valuable tool to detect changes in pathogen and AMR profiles and inform empiric antibiotic recommendations for neonatal units in resource-limited settings.
Authors: Despoina Gkentzi; Christina Kortsalioudaki; Benjamin Campbell Cailes; Theoklis Zaoutis; John Kopsidas; Maria Tsolia; Nikos Spyridis; Soultana Siahanidou; Kosmas Sarafidis; Paul T Heath; Gabriel Dimitriou Journal: Arch Dis Child Fetal Neonatal Ed Date: 2018-06-28 Impact factor: 5.747
Authors: Majeda S Hammoud; Abdullah Al-Taiar; Sameer Y Al-Abdi; Hussain Bozaid; Anwar Khan; Laila M AlMuhairi; Moghis Ur Rehman Journal: Int J Infect Dis Date: 2017-01-11 Impact factor: 3.623
Authors: Eric Giannoni; Philipp K A Agyeman; Martin Stocker; Klara M Posfay-Barbe; Ulrich Heininger; Ben D Spycher; Sara Bernhard-Stirnemann; Anita Niederer-Loher; Christian R Kahlert; Alex Donas; Antonio Leone; Paul Hasters; Christa Relly; Thomas Riedel; Claudia Kuehni; Christoph Aebi; Christoph Berger; Luregn J Schlapbach Journal: J Pediatr Date: 2018-07-24 Impact factor: 4.406
Authors: W C van der Zwet; A M Kaiser; R M van Elburg; J Berkhof; W P F Fetter; G A Parlevliet; C M J E Vandenbroucke-Grauls Journal: J Hosp Infect Date: 2005-10-10 Impact factor: 3.926
Authors: Abdullah Al-Taiar; Majeda S Hammoud; Liu Cuiqing; Jimmy K F Lee; Kin-Man Lui; Narongsak Nakwan; David Isaacs Journal: Arch Dis Child Fetal Neonatal Ed Date: 2012-08-31 Impact factor: 5.747
Authors: Rudzani C Mashau; Susan T Meiring; Angela Dramowski; Rindidzani E Magobo; Vanessa C Quan; Olga Perovic; Anne von Gottberg; Cheryl Cohen; Sithembiso Velaphi; Erika van Schalkwyk; Nelesh P Govender Journal: Lancet Glob Health Date: 2022-08 Impact factor: 38.927
Authors: A Dramowski; M Aucamp; A Bekker; S Pillay; K Moloto; A C Whitelaw; M F Cotton; S Coffin Journal: Antimicrob Resist Infect Control Date: 2021-02-12 Impact factor: 4.887
Authors: Moses Vurayai; Jonathan Strysko; Kgomotso Kgomanyane; One Bayani; Margaret Mokomane; Tichaona Machiya; Tonya Arscott-Mills; David M Goldfarb; Andrew P Steenhoff; Carolyn McGann; Britt Nakstad; Alemayehu Gezmu; Melissa Richard-Greenblatt; Susan Coffin Journal: Antimicrob Resist Infect Control Date: 2022-01-24 Impact factor: 4.887